**Abstract**

The objective of this work is to examine the efficiency and record the adverse effects of amisulpride in treatment of patients with residual schizophrenia.

The research includes 31 patients with symptoms of residual schizophrenia which are persisting for over a year, and which were previously treated with second generation antipsychotics. The patients treated with Clozapine were not included. Amisulpride, as a sole antipsychotic, was applied to all patients during the course of treatment in this research. The average daily dose of Amisulpride used was about 450 mg, and dosing range was from 200 to 700 mg, depending on symptomatology present. Clinical evaluation was conducted during an eight-week period, by using psychometric scales: CGI (severity of illness and general improvement subscales), BPRS, and PANSS with recording of adverse effects of Amisulpride.

After analysis and statistical processing of data, we obtained the results that show that there is a statistically significant difference of scores at the beginning of treatment and after eight weeks of treatment when it comes to negative symptoms scale (Z=-2,202; p=0,028) and total PANSS score (Z=-1,975; p=0,048). When it comes to BPRS scale there is a statistically significant difference in scores before the treatment, after 2 weeks, after 4 weeks and after 8 weeks of treatment (p=0.027). We've also obtained a result that shows statistically significant difference of scores in CGI -- general improvement scale (p=0.045). More significant adverse effects were recorded in 4 patients (hyperprolactinemia in 2 patients, amenorrhea in 1 patient, and impotence in 1 patient).

Based on the results obtained we can conclude that amisulpride has shown significant efficiency in treatment of residual schizophrenia with dominant effects on negative symptoms, with well tolerability for patients and minor manifestation of adverse actions.
